Treatment of metastatic pancreatic adenocarcinoma

Abstract

A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.

What is claimed is: 
     
         1 . A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof, wherein the subject is post first-line treatment against said metastatic pancreatic adenocarcinoma, the method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma. 
     
     
         2 . The method of  claim 1 , wherein said anti PD-1 is pembrolizumab. 
     
     
         3 . The method of  claim 1 , wherein said chemotherapy comprises a plurality of chemotherapeutic agents. 
     
     
         4 . The method of  claim 1 , wherein said chemotherapy comprises irinotecan, fluorouracil (5-FU) and leucovorin (LV). 
     
     
         5 . The method of  claim 4 , wherein said irinotecan is liposome-encapsulated. 
     
     
         6 . The method of  claim 1 , wherein said peptide is administered subcutaneously (SC). 
     
     
         7 . The method of  claim 1 , wherein said peptide is administered at a dose of 1.25 mg/kg. 
     
     
         8 . The method of  claim 1 , wherein said anti PD-1 is administered intravenously (IV). 
     
     
         9 . The method of  claim 1 , wherein said chemotherapy is administered intravenously. 
     
     
         10 . The method of  claim 1 , wherein said treatment comprises a monotherapy period with said peptide followed by a combination therapy with said peptide, said anti PD-1 and said chemotherapy. 
     
     
         11 . The method of  claim 10 , wherein said combination therapy is repeated every 2 weeks with said chemotherapy and every 3 weeks with said anti PD-1. 
     
     
         12 . The method of  claim 10 , wherein said monotherapy is performed on Days 1-5, daily.